Clinical trial results:
A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03

Summary

EudraCT number	2018-000236-97
Trial protocol	HU BG
Global end of trial date	25 December 2021

Results information

Result version number	v1 (current)
This version publication date	21 October 2022
First version publication date	21 October 2022

Trial information

Trial identification

Sponsor protocol code	TX05-03E

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04109391
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Tanvex Biologics Corporation
Sponsor organisation address	2030 Main Street, Suite 1050, CA 96214, Irvine, United States,
Public contact	Jennifer Lai, Tanvex Biologics Corp., Tanvex Biologics Corporation, +1 949-483-8507, jennifer.lai@tanvex.com
Scientific contact	Jennifer Lai, Tanvex Biologics Corp., Tanvex Biologics Corporation, +1 949-483-8507, jennifer.lai@tanvex.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 December 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 December 2021
Global end of trial reached?	Yes
Global end of trial date	25 December 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

• To collect safety, tolerability, and immunogenicity data for single agent Herceptin or TX05 in the adjuvant setting in subjects with early HER2-positive breast cancer who completed neoadjuvant treatment and primary resection in Protocol TX05-03.
• To collect safety, tolerability, and immunogenicity data following a single transition from neoadjuvant Herceptin to adjuvant TX05 in this population.
• To collect disease-free survival (DFS) and overall survival (OS) data in this population.

Protection of trial subjects:

Independent Ethics Committee or Institutional Review Board
Written approval of the protocol, the final informed consent document, relevant supporting material and subject recruitment information was obtained from the independent ethics committee (IEC)/institutional review board (IRB) of each site prior to study initiation.
Ethical Conduct of the Study
The Sponsor or designee implemented and maintained quality control and quality assurance procedures with written standard operating procedures (SOPs) to ensure that the study was conducted and data were generated, documented and reported in compliance with the protocol, International Council for Harmonisation (ICH) Good Clinical Practice (GCP), and applicable regulatory requirements.
This study was conducted in accordance with the provisions of the Declaration of Helsinki (October 1996) and all revisions thereof, and in accordance with Food and Drug Administration (FDA) regulations (code of federal regulations [CFR], Sections 312.50 and 312.56) and with ICH GCP (CPMP 135/95).
Subject Information and Consent
Informed consent was obtained from each subject before the subject was admitted to the study. The investigator was not to undertake any investigation specifically required for the clinical study until valid consent had been obtained. The consent form, with the date and time of day when it was signed, was to be retained by the investigator as part of the study records. A copy of the signed informed consent form was given to the subject.

Background therapy:

Concomitant medications administered for any reason were locally-approved and doses used and regimens were considered standard of care for the treated indication. Medications and (non-drug treatments) were monitored continuously by the investigator. Treatment for co-morbidities, disease signs and symptoms and treatment-emergent adverse events (TEAEs) were provided as necessary in the judgment of the investigator. Supportive care included premedication with antiemetics to limit study drug-related nausea and vomiting.
Subjects could receive prophylaxis of treatment-induced diarrhea. Anti-inflammatory or narcotic analgesics were offered as needed.
Prophylactic use of hematopoietic growth factors to support neutrophil or platelet counts according to local standard of care was permitted during this study. Subjects who entered the study on stable doses of erythropoietin or darbepoietin could continue this treatment, and subjects could start either drug during the study at the discretion of the investigator.
Subjects with neutropenic fever or infection were treated promptly and could receive therapeutic colony-stimulating factors if appropriate. Packed red blood cell and platelet transfusions were administered as clinically indicated. All concomitant medications and treatments were to be recorded in the subject's source documents and entered into the eCRF, available during study monitor visits, and included in SAE reports. Surgery during study participation to manage breast cancer lesions other than definitive surgery for the targeted tumor lesion post-neoadjuvant therapy was discouraged unless medically necessary in the judgment of the investigator. In this case, the subject was to be discontinued from the study prior to the surgical procedure. In such cases, the EOS/ET Visit was to be completed. No other investigational drug was to be used during treatment on this protocol, and concurrent participation in another clinical study was not allowed.

Evidence for comparator: -	
Actual start date of recruitment	20 August 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belarus: 15
Country: Number of subjects enrolled	Chile: 7
Country: Number of subjects enrolled	Georgia: 16
Country: Number of subjects enrolled	India: 41
Country: Number of subjects enrolled	Mexico: 14
Country: Number of subjects enrolled	Peru: 26
Country: Number of subjects enrolled	Philippines: 9
Country: Number of subjects enrolled	Russian Federation: 139
Country: Number of subjects enrolled	Ukraine: 70
Country: Number of subjects enrolled	Hungary: 1
Worldwide total number of subjects	338
EEA total number of subjects	1

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	266
From 65 to 84 years	72
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Females ≥ 18 years of age
Completed neoadjuvant treatment (regardless of treatment arm) in the TX05/ Herceptin neoadjuvant study.
Successfully underwent surgical resection of their primary tumor with no evidence of residual disease (as determined by local assessment) and no other adjuvant therapy, other than trastuzumab, was planned.

Pre-assignment

Screening details:

A CT scan or MRI (only if CT scan cannot be performed) of the chest, abdomen, and pelvis was required at Screening for all subjects. Depending on the adequacy for evaluation of disease, a combination of CT without contrast had to most often be used. Final tumor assessment at the EOS/ET Visit included repeat CT scan or MRI.

Pre-assignment period milestones

Number of subjects started	344[1]
Number of subjects completed	338

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screening failure: 5
Reason: Number of subjects	Not assigned: 1

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: In total, 344 subjects were screened, of which 6 subjects were considered screen failures. All of the 338 randomized subjects initiated protocol treatment. Of those subjects who initiated protocol treatment, 175 subjects received TX05 only, 82 subjects received Herceptin only and 81 subjects transitioned from Herceptin to TX05.

Period 1

Period 1 title	Treatment Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	TX05 only

Arm description:

This is an extension study for subjects who were treated in the prior TX05/Herceptin neoadjuvant study (Protocol TX05-03) and successfully underwent surgical resection. Subjects were randomized to receive adjuvant treatment with single agent TX05 for up to 13 treatment cycles.

Arm type	Experimental
Investigational medicinal product name	TX05
Investigational medicinal product code	TX05
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

TX05 8 mg/kg body weight was administered by 60-minute IV infusion on Day 1 of treatment Cycle 1 and thereafter
6 mg/kg body weight every 3 weeks until Cycle 13.

Arm title	Herceptin Only

Arm description:

This is an extension study for subjects who were treated in the prior TX05/Herceptin neoadjuvant study (Protocol TX05-03) and successfully underwent surgical resection. Subjects were randomized to receive adjuvant treatment with single agent Herceptin for up to 13 treatment cycles.

Arm type	Active comparator
Investigational medicinal product name	Herceptin
Investigational medicinal product code	Herceptin
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Herceptin 8 mg/kg body weight was administered by 60-minute IV infusion on Day 1 of treatment Cycle 1 and thereafter 6 mg/kg body weight every 3 weeks until Cycle 13.

Arm title	Herceptin/TX05 Transition

Arm description:

This is an extension study for subjects who were treated in the prior TX05/Herceptin neoadjuvant study (Protocol TX05-03) and successfully underwent surgical resection. Subjects were randomized to receive adjuvant treatment with single agent Herceptin or TX05 for up to 13 treatment cycles. 81 subjects transitioned from Herceptin to TX05.

Arm type	Experimental
Investigational medicinal product name	TX05 or Herceptin
Investigational medicinal product code	TX05
Other name	
Pharmaceutical forms	Injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

TX05 8 mg/kg body weight was administered by 60-minute IV infusion on Day 1 of treatment Cycle 1 and thereafter
6 mg/kg body weight every 3 weeks until Cycle 13.

Number of subjects in period 1	TX05 only	Herceptin Only	Herceptin/TX05 Transition
Started	175	82	81
Completed	165	77	77
Not completed	10	5	4
Consent withdrawn by subject	2	-	-
Adverse event, non-fatal	2	2	-
Not specified	3	1	-
Pregnancy	1	-	-
Lost to follow-up	-	-	1
Disease Progression	2	2	3

Baseline characteristics

Reporting groups

Reporting group title	Treatment Period

Reporting group description: -

Reporting group values	Treatment Period	Total	
Number of subjects	338	338	
Age categorical			
TX05 only = 130 subjects (age in between 18 to 64) Herceptin only = 70 subjects (age in between 18 to 64) Herceptin/TX05 Transition = 66 subjects (age in between 18 to 64) TX05 only = 45 subject (age in between 65 to 84) Herceptin only = 12 subjects (age in between 65 to 84) Herceptin/TX05 Transition = 15 subjects (age in between 65 to 84)			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	266	266	
From 65-84 years	72	72	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	54.6		
standard deviation	± 10.95	-	
Gender categorical			
Units: Subjects			
Female	338	338	
Male	0	0	

Subject analysis sets

Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis

Subject analysis set description:

The safety analysis was carried with the safety population according to the treatment they actually received.

Reporting group values	Safety Population		
Number of subjects	338		
Age categorical			
TX05 only = 130 subjects (age in between 18 to 64) Herceptin only = 70 subjects (age in between 18 to 64) Herceptin/TX05 Transition = 66 subjects (age in between 18 to 64) TX05 only = 45 subject (age in between 65 to 84)			

Herceptin only = 12 subjects (age in between 65 to 84) Herceptin/TX05 Transition = 15 subjects (age in between 65 to 84)			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)	266		
From 65-84 years	72		
85 years and over			
Age continuous			
Units: years			
arithmetic mean	54.6		
standard deviation	± 10.95		
Gender categorical			
Units: Subjects			
Female	338		
Male	0		

End points

End points reporting groups

Reporting group title	TX05 only

Reporting group description:

This is an extension study for subjects who were treated in the prior TX05/Herceptin neoadjuvant study (Protocol TX05-03) and successfully underwent surgical resection. Subjects were randomized to receive adjuvant treatment with single agent TX05 for up to 13 treatment cycles.

Reporting group title	Herceptin Only

Reporting group description:

This is an extension study for subjects who were treated in the prior TX05/Herceptin neoadjuvant study (Protocol TX05-03) and successfully underwent surgical resection. Subjects were randomized to receive adjuvant treatment with single agent Herceptin for up to 13 treatment cycles.

Reporting group title	Herceptin/TX05 Transition

Reporting group description:

This is an extension study for subjects who were treated in the prior TX05/Herceptin neoadjuvant study (Protocol TX05-03) and successfully underwent surgical resection. Subjects were randomized to receive adjuvant treatment with single agent Herceptin or TX05 for up to 13 treatment cycles. 81 subjects transitioned from Herceptin to TX05.

Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis

Subject analysis set description:

The safety analysis was carried with the safety population according to the treatment they actually received.

Primary: Disease-Free Survival (DFS)

End point title	Disease-Free Survival (DFS)[1]

End point description:

Recurrence of Breast Cancer or a Diagnosis of a second primary cancer.
NOTE:
This is an extension trial and had no formal primary endpoint. The parameter (DFS) was regarded as of highest clinical relevance.

End point type	Primary

End point timeframe:

Time from randomization in the neoadjuvant study TX05-03 to the documentation of a first failure, where a failure is the recurrence of breast cancer, a diagnosis of a second primary cancer.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This extension trial had no formal primary endpoint. No statistical analysis were performed for this end point.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of events	6	5	3	14

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Overall Survival (OS)

End point title	Overall Survival (OS)

End point description:

Overall survival.

End point type	Other pre-specified

End point timeframe:

From randomization in the neoadjuvant study until death from any cause.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of events	0	0	1	1

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of treatment-emergent adverse events (TEAEs)

End point title	Incidence of treatment-emergent adverse events (TEAEs)

End point description:

Treatment emergent adverse event is defined as any AEs newly occurring on or after the first dose of study drug of study TX05-03E or severity becomes worse on or after the first dose of study drug of the study TX05-03E.

End point type	Other pre-specified

End point timeframe:

From Day 1 of Cycle 1 of study treatment to EOS/ET week 45.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	93	46	30	169

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of study drug related TEAEs

End point title	Incidence of study drug related TEAEs

End point description:

Treatment emergent adverse event is defined as any AEs newly occurring on or after the first dose of study drug of study TX05-03E or severity becomes worse on or after the first dose of study drug of the study TX05-03E.

End point type	Other pre-specified

End point timeframe:

From Day 1 of Cycle 1 of study treatment to EOS/ET week 45.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	36	20	9	65

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of serious AEs

End point title	Incidence of serious AEs

End point description:

Treatment emergent adverse event is defined as any AEs newly occurring on or after the first dose of study drug of study TX05-03E or severity becomes worse on or after the first dose of study drug of the study TX05-03E.

End point type	Other pre-specified

End point timeframe:

From Day 1 of Cycle 1 of study treatment to EOS/ET week 45.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	4	3	2	9

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of study drug related SAEs

End point title	Incidence of study drug related SAEs

End point description:

Treatment emergent adverse event is defined as any AEs newly occurring on or after the first dose of

study drug of study TX05-03E or severity becomes worse on or after the first dose of study drug of the study TX05-03E.

End point type	Other pre-specified

End point timeframe:

From Day 1 of Cycle 1 of study treatment to EOS/ET week 45.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of anti-drug antibodies (ADA)

End point title	Incidence of anti-drug antibodies (ADA)

End point description:

Subjects with positive ADA.

End point type	Other pre-specified

End point timeframe:

From prior to initiation of infusion of study drug at Cycle 6 week 15.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	1	1	4	6

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of anti-drug antibodies (ADA)

End point title	Incidence of anti-drug antibodies (ADA)

End point description:

Subjects with positive ADA

End point type	Other pre-specified

End point timeframe:

From prior to initiation of infusion of study drug at EOS/ET week 45.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	4	1	2	7

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of neutralizing antibodies (Nab)

End point title	Incidence of neutralizing antibodies (Nab)

End point description:

Subjects with positive Nab.

End point type	Other pre-specified

End point timeframe:

From prior to initiation of infusion of study drug at Cycle 6 week 15.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Incidence of neutralizing antibodies (Nab)

End point title	Incidence of neutralizing antibodies (Nab)

End point description:

Subjects with positive Nab.

End point type	Other pre-specified

End point timeframe:

From prior to initiation of infusion of study drug at EOS/ET week 45.

End point values	TX05 only	Herceptin Only	Herceptin/TX05 Transition	Safety Population
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	175	82	81	338
Units: Number of subjects	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
From Day 1 of Cycle 1 of study treatment to EOS/ET week 45.	
Adverse event reporting additional description:	
Treatment emergent adverse event is defined as any AEs newly occurring on or after the first dose of study drug of study TX05-03E or severity becomes worse on or after the first dose of study drug of the study TX05-03E.	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	24.1

Reporting groups	
Reporting group title	Safety population TX05
Reporting group description:	
Patients on TX05	
Reporting group title	Safety population Herceptin
Reporting group description:	
Patient on Herceptin	
Reporting group title	Safety population Herceptin/ TX05 Transition
Reporting group description:	
Patients on Herceptin in main study and randomized to TX05 at the beginning of the extension period.	

Serious adverse events	Safety population TX05	Safety population Herceptin	Safety population Herceptin/ TX05 Transition
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 175 (2.29%)	3 / 82 (3.66%)	2 / 81 (2.47%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 175 (0.00%)	1 / 82 (1.22%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 175 (0.00%)	0 / 82 (0.00%)	1 / 81 (1.23%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Hepatic failure			
subjects affected / exposed	0 / 175 (0.00%)	0 / 82 (0.00%)	1 / 81 (1.23%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 175 (0.57%)	0 / 82 (0.00%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 175 (0.00%)	1 / 82 (1.22%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	1 / 175 (0.57%)	0 / 82 (0.00%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	2 / 175 (1.14%)	0 / 82 (0.00%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 175 (0.00%)	1 / 82 (1.22%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 175 (0.00%)	1 / 82 (1.22%)	0 / 81 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Safety population TX05	Safety population Herceptin	Safety population Herceptin/ TX05 Transition
Total subjects affected by non-serious adverse events			
subjects affected / exposed	49 / 175 (28.00%)	15 / 82 (18.29%)	15 / 81 (18.52%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	10 / 175 (5.71%)	2 / 82 (2.44%)	1 / 81 (1.23%)
occurrences (all)	11	6	1
Aspartate aminotransferase increased			
subjects affected / exposed	9 / 175 (5.14%)	1 / 82 (1.22%)	3 / 81 (3.70%)
occurrences (all)	10	3	3
Injury, poisoning and procedural complications			
Radiation skin injury			
subjects affected / exposed	13 / 175 (7.43%)	5 / 82 (6.10%)	0 / 81 (0.00%)
occurrences (all)	13	5	0
Nervous system disorders			
Headache			
subjects affected / exposed	9 / 175 (5.14%)	5 / 82 (6.10%)	3 / 81 (3.70%)
occurrences (all)	13	8	4
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	10 / 175 (5.71%)	4 / 82 (4.88%)	3 / 81 (3.70%)
occurrences (all)	12	4	4
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	14 / 175 (8.00%)	1 / 82 (1.22%)	0 / 81 (0.00%)
occurrences (all)	25	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	7 / 175 (4.00%)	5 / 82 (6.10%)	2 / 81 (2.47%)
occurrences (all)	8	5	2
Infections and infestations			
Respiratory tract infection			

subjects affected / exposed occurrences (all)	6 / 175 (3.43%) 6	2 / 82 (2.44%) 2	5 / 81 (6.17%) 5

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Not applicable

Notes: